UKIACR average (population) | UKIACR average (country) | England | Scotland | Wales | Northern Ireland | Republic of Ireland | |
---|---|---|---|---|---|---|---|
All invasive xnmsc | 19.5% | 18.7% | 20.0% | 20.1% | 10.9% | 25.5% | 17.0% |
All xnmsc 0-24 | 12.9% | 12.1% | 13.5% | 10.0% | 7.3% | 20.3% | 9.1% |
All xnmsc 25-59 | 22.2% | 21.7% | 22.6% | 24.0% | 13.4% | 29.8% | 18.9% |
All xnmsc 60-79 | 21.8% | 20.5% | 22.5% | 22.1% | 12.0% | 28.0% | 18.0% |
All xnmsc 80+ | 11.4% | 10.6% | 11.8% | 10.7% | 6.2% | 13.5% | 10.9% |
Haematology | 8.7% | 8.0% | 9.1% | 8.2% | 3.6% | 11.7% | 7.5% |
Head and Neck | 54.8% | 52.2% | 56.6% | 48.7% | 38.5% | 66.6% | 50.4% |
Lower GI | 12.4% | 11.8% | 12.6% | 11.6% | 8.5% | 13.3% | 13.0% |
Upper GI | 17.7% | 16.6% | 17.9% | 16.2% | 11.4% | 12.1% | 25.3% |
HPB | 2.3% | 2.9% | 2.2% | 2.3% | 1.1% | 4.9% | 3.9% |
Trachea, Bronchus & Lung | 26.8% | 25.7% | 27.1% | 30.1% | 17.6% | 31.9% | 21.7% |
Melanoma | 0.9% | 1.2% | 0.9% | 0.4% | 1.3% | 2.0% | 1.3% |
Breast | 35.1% | 33.4% | 36.0% | 38.4% | 14.0% | 50.0% | 28.6% |
Cervix | 39.6% | 42.7% | 38.1% | 49.1% | 29.3% | 54.3% | 42.6% |
Other Female Genitals | 14.3% | 15.1% | 14.1% | 15.2% | 14.0% | 18.2% | 13.8% |
Prostate | 17.1% | 14.5% | 18.5% | 10.7% | 5.8% | 26.0% | 11.3% |
Kidney | 5.2% | 5.2% | 5.2% | 5.7% | 4.4% | 6.5% | 4.2% |
Bladder | 15.4% | 14.2% | 15.9% | 14.7% | 11.6% | 19.7% | 9.1% |
Brain and CNS | 43.2% | 43.9% | 43.1% | 42.2% | 28.1% | 54.7% | 51.5% |
Thyroid & other endocrine glands | 29.7% | 25.5% | 31.8% | 25.0% | 18.4% | 39.1% | 13.1% |
CUP | 11.2% | 9.9% | 11.9% | 8.2% | 6.1% | 12.9% | 10.5% |
Other invasive cancer | 15.2% | 12.3% | 16.3% | 12.5% | 8.4% | 13.5% | 10.8% |
Breast in situ | 29.5% | 30.7% | 29.1% | 38.6% | 15.2% | 38.0% | 32.8% |
Cervix in situ | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% |
Other tumours | 1.0% | 1.1% | 1.1% | 0.4% | 0.6% | 2.9% | 0.7% |
Non-Melanoma Skin Cancer | 1.0% | 1.2% | 1.1% | 0.5% | 1.7% | 1.7% | 0.9% |